Non small cell lung cancer

• Health & Medicine

Potentially life-extending treatment for lung cancer available in England

A potentially life-extending treatment for some people with non small cell lung cancer (NSCLC) will now be available on the NHS in England. A potentially life-extending treatment for some people with non small cell lung cancer (NSCLC) will now be available on the NHS in England.

9 February 2021

• Health & Medicine

Three new cancer drugs approved for NHS in Scotland

The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma. The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.

21 January 2021

• Health & Medicine

Targeted drug for lung cancer approved for NHS use in England

The National Institute for Health and Care Excellence has approved the drug osimertinib to treat some adults in England with untreated, advanced lung cancer. The National Institute for Health and Care Excellence has approved the drug osimertinib to treat some adults in England with untreated, advanced lung cancer.

11 September 2020

• For Supporters

The power of philanthropy: TRACERx

In the first of a new blog series on the power of philanthropy, we look at TRACERx – the first longitudinal, large-scale study of lung cancer evolution. In the first of a new blog series on the power of philanthropy, we look at TRACERx – the first longitudinal, large-scale study of lung cancer evolution.

4 June 2020

• Health & Medicine

Three new treatment options approved for NHS use in Scotland

The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland

26 March 2020

• Health & Medicine

Targeted lung cancer treatment gets initial ‘no’ for NHS in England

Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua).  Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua). 

4 February 2020

• Health & Medicine

Lung cancer immunotherapy combo added to Cancer Drugs Fund

Combining an immunotherapy with chemotherapy has been recommended as a treatment for some patients with lung cancer on the NHS in England. Combining an immunotherapy with chemotherapy has been recommended as a treatment for some patients with lung cancer on the NHS in England.

8 August 2019

• Health & Medicine

Kidney and lung cancer drugs approved on the NHS in Scotland

One kidney cancer treatment and two lung cancer drugs have been recommended for use on the NHS in Scotland. One kidney cancer treatment and two lung cancer drugs have been recommended for use on the NHS in Scotland.

12 June 2019

• Health & Medicine

Lung cancer treatment combo given initial NHS ‘no’ in England

A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England. A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England.

12 February 2019

• Health & Medicine

Lung cancer immunotherapy drug approved for England

The lung cancer immunotherapy drug pembrolizumab has been made widely available on the NHS in England after a price deal was reached. The lung cancer immunotherapy drug pembrolizumab has been made widely available on the NHS in England after a price deal was reached.

6 June 2018

• Health & Medicine

Cancer Research UK and Biotecnol to trial new immuno-oncology treatment for advanced tumours

Cancer Research UK and Biotecnol Limited will trial an experimental immuno-oncology treatment for some patients with advanced tumours. Cancer Research UK and Biotecnol Limited will trial an experimental immuno-oncology treatment for some patients with advanced tumours.

10 August 2017

• Health & Medicine

Two clinical trials show promise with different targeted drugs for lung cancer

Two drugs targeting different gene faults in lung cancer have shown potential to be better than those already available. Two drugs targeting different gene faults in lung cancer have shown potential to be better than those already available.

6 June 2017